Biogen's Alzheimer's Drug Sales Surge, Shares Rise 6% - Wubba Lubba Dub Dub!

Leqembi Brings Big Bucks

Yo Morty! We gotta check out this news about Leqembi raking in $19 million in sales for the quarter! That's like more than double what it made last year. It's like watching Mr. Meeseeks fulfilling his task Morty.

Bottlenecks and Brain Scans Slow Uptake

Looks like the uptake of Leqembi is slower than Jerry realizing he's a Jerry. The drug requires twice monthly infusions and regular brain scans. Talk about a hassle Morty.

Newly Launched Drugs Hit the Mark

Apart from Leqembi Biogen's Skyclarys and Zurzuvae are also making waves. It's like Summer discovering a new dimension in her closet or something Morty.

Multiple Sclerosis Drugs Face Competition

Biogen's multiple sclerosis drugs are facing off against cheaper generics Morty. It's like a showdown between Rick and Evil Rick but with medications.

Spinraza's Revenue Slumps

Spinraza's revenue took a hit below expectations. Guess it's like Birdperson getting caught in a rough patch Morty. Things don't always go as planned.

Biosimilar Drugs Maintain Steady Sales

The biosimilar drugs maintained steady sales Morty. It's like Unity trying to balance all the different personalities. Maintaining harmony is key Morty.